Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody

Öz

Background: Patients with severe asthma are at particularly higher risk for SARS-CoV-2 infection due to exacerbations of asthma caused by viral infections, SARS-CoV-2 viral load at hospitals and challenges in access to healthcare facilities due to some restrictions. Thus, we aimed to investigate effect of the SARS-CoV-2 pandemic on treatment and control of asthma in patients receiving monoclonal antibody MAb treatment. Methods: The patients, who were using MAb for treatment of for severe persistent asthma, were enrolled. Each patient was asked to fill in a validated Coronavirus anxiety scale and a mini survey. Results: Sixty-two patients (Female: 44; Male: 18), who were given MAb therapy for asthma, were enrolled. Patients’ treatment compliance was 56.5% in March-April-May 2020. Curfew was the most common government-related factors that have influenced patients’ compliance to treatment (35.5%). The most common individual factor was fear of contracting SARS-CoV-2 (40.3%). Exacerbated symptoms and need for additional treatment for asthma were significantly more common in patients, who were not compliant to treatment, compared to the patients adherent to MAb treatment (p: 0.034 and p:0.013) Conclusion: Treatment compliance has reduced in patients, who take MAb treatment, due to both governmental and individual reasons. This has led to more common admissions to emergency department with complaints of asthma and need for an additional treatment. All these findings indicate that patients should maintain their MAb treatments despite the pandemic and that they should minimize the risk of SARS-CoV-2 infection by following the recommendations published in the guidelines.

Anahtar Kelimeler

• SARS-CoV-
• omalizumab
• severe asthma
• mepolizumab

Proje Numarası

2021/018

Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody

Öz

Amaç: Ağır astımı olan hastalar, viral enfeksiyonların neden olduğu astım alevlenmeleri, hastanelerdeki SARS-CoV-2 viral yükü ve bazı kısıtlamalar nedeniyle sağlık tesislerine erişimdeki zorluklar nedeniyle özellikle SARS-CoV-2 enfeksiyonu için daha yüksek risk altındadır. Bundan dolayı monoklonal antikor (MAb) tedavisi alan hastalarda SARS-CoV-2 pandemisinin astım tedavisi ve kontrolü üzerindeki etkisini araştırılması amaçlandı. Materyel-Metod: Ağır persistan astım tedavisi için MAb kullanan hastalar çalışmaya dahil edildi. Her hastadan onaylanmış bir Coronavirüs kaygı ölçeği ve mini bir anket doldurması istendi. Bulgular:Ağır Astım nedeniyle MAb tedavisi alan 62 hasta (Kadın: 44; Erkek: 18) çalışmaya alındı. Mart-Nisan-Mayıs 2020'de hastaların tedaviye uyumu %56.5 idi. Sokağa çıkma yasağı, hastaların tedaviye uyumunu (%35.5) etkileyen en yaygın hükümetle ilgili faktörolarak saptandı. En yaygın bireysel faktör, SARS-CoV-2 kapma korkusuydu (%40.3). Tedaviye uyum sağlamayan hastalarda, MAb tedavisine uyan hastalara göre, semptomlarda artış ve astım için ek tedavi gereksinimi anlamlı olarak daha fazlaydı (p:0.034 ve p:0.013) Sonuç: MAb tedavisi alan hastalarda hem resmi hem de bireysel nedenlerle tedaviye uyum azalmıştır. Bu durum acil servise astım şikayetleri ve ek tedavi ihtiyacı ile daha sık başvurulara neden olmuştur. Tüm bu bulgular, hastaların pandemiye rağmen MAb tedavilerini sürdürmeleri gerektiğini ve kılavuzlarda yayınlanan tavsiyelere uyarak SARS-CoV-2 enfeksiyon riskini en aza indirmeleri gerektiğini göstermektedir.

Anahtar Kelimeler

• COVİD 19
• omalizumab
• ağır astım
• mepolizumab

Destekleyen Kurum

YOK

Proje Numarası

2021/018

Kaynakça

1. 1. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343-60.
2. 2. Lee JH, Lee Y, Lee SY, Van Bever H, Lou H, Zhang L, et al. Management of Allergic Patients During the COVID-19 Pandemic in Asia. Allergy Asthma Immunol Res. 2020;12(5):783-91.
3. 3. Worldometer. COVID-19 Corona virus pandemic 2021, January 7. Available from: https://www.worldometers.info/coronavirus/?zarsrc=130.
4. 4. Rebmann T, Vassallo A, Holdsworth JE. Availability of personal protective equipment and infection prevention supplies during the first month of the COVID-19 pandemic: A national study by the APIC COVID-19 task force. Am J Infect Control. 2021 Apr;49(4):434-437
5. 5. Giorgi G, Lecca LI, Alessio F, Finstad GL, Bondanini G, Lulli LG, et al. COVID-19-Related Mental Health Effects in the Workplace: A Narrative Review. Int J Environ Res Public Health. 2020;27;17(21). 6. Dubey S, Biswas P, Ghosh R, Chatterjee S, Dubey MJ, Chatterjee S, et al. Psychosocial impact of COVID-19. Diabetes Metab Syndr. 2020;14(5):779-88.
6. 7. Bousquet J, Jutel M, Akdis CA, Klimek L, Pfaar O, Nadeau KC, et al. ARIA-EAACI statement on asthma and COVID-19.Allergy. 2021;76(3):689-697. 8. Atayık E, Aytekin G. SARS-CoV-2 in a Patient with Persistent Asthma Taking Omalizumab: The First Case in Turkey. Asthma Allergy Immunology. 2020;18:23-6.
7. 9. Öztürk AB, Bavbek S. Role of SARS-CoV-2 in Asthma Exacerbations. Asthma Allergy Immunology. 2020;18:8-10.
8. 10. Biçer İ, Çakmak C, Demir H, Kurt ME. Koronavirüs anksiyete ölçeği kısa formu: Türkçe geçerlik ve güvenirlik çalışması. Anadolu Kliniği Tıp Bilimleri Dergisi. 2020;25(Special Issue on COVID 19):216-25.

9. 11. Ozturk AB, Baccioglu A, Soyer O, Civelek E, Sekerel BE, Bavbek S. Change in Allergy Practice during the COVID-19 Pandemic. Int Arch Allergy Immunol. 2020;15:1-4.
10. 12. Jeffery MM, D'Onofrio G, Paek H, Platts-Mills TF, Soares WE, 3rd, Hoppe JA, et al. Trends in Emergency Department Visits and Hospital Admissions in Health Care Systems in 5 States in the First Months of the COVID-19 Pandemic in the US. JAMA Intern Med. 2020;180(10):1328-33.
11. 13. Cildag S, Senturk T. The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response. Postepy Dermatol Alergol. 2018;35(5):516-9. 14. Gill MA, Liu AH, Calatroni A, Krouse RZ, Shao B, Schiltz A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141(5):1735-43 e9.
12. 15. Cardet JC, Casale TB. New insights into the utility of omalizumab. J Allergy Clin Immunol. 2019;143(3):923-6 e1.
13. 16. Wang T, Hou W, Fu Z. Preventative effect of OMZ-SPT on lipopolysaccharide-induced acute lung injury and inflammation via nuclear factor-kappa B signaling in mice. Biochem Biophys Res Commun. 2017;485(2):284-9.
14. 17. Sabogal Pineros YS, Bal SM, van de Pol MA, Dierdorp BS, Dekker T, Dijkhuis A, et al. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study. Am J Respir Crit Care Med. 2019;199(4):508-17.
15. 18. Abdelmaksoud A, Goldust M, Vestita M. Omalizumab and COVID-19 treatment: Could it help? Dermatol Ther. 2020;33(4):e13792.
16. 19. Cardinale F, Ciprandi G, Barberi S, Bernardini R, Caffarelli C, Calvani M, et al. Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. Ital J Pediatr. 2020;46(1):84.
17. 20. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK, et al. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organ J. 2020;13(5):100126.
18. 21. Timmermann H, Mailander C. Home Self-Administration of Biologics - A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians. Pneumologie. 2020;74(2):103-11.
19. 22. Menzella F, Ferrari E, Ferrucci SM, Lombardi E, Alfano S, Bonavita O, et al. Self-administration of omalizumab: why not? A literature review and expert opinion. Expert Opin Biol Ther. 2021;13:1-9.
20. 23. Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab. J Allergy Clin Immunol Pract. 2020;8(2):565-72.
21. 24. Torales J, O'Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry. 2020;66(4):317-20.
22. 25. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 202;89:531-42.
23. 26. Cao W, Fang Z, Hou G, Han M, Xu X, Dong J, et al. The psychological impact of the COVID-19 epidemic on college students in China. Psychiatry Res. 2020;287:112934.